Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC

Immunotherapy, especially anti-programmed cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) treatment has significantly improved the survival of non-small cell lung cancer (NSCLC) patients. However, the overall response rate remains unsatisfactory. Many factors affect the outcome of a...

Descripción completa

Detalles Bibliográficos
Autores principales: Niu, Mengke, Yi, Ming, Li, Ning, Luo, Suxia, Wu, Kongming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7923338/
https://www.ncbi.nlm.nih.gov/pubmed/33653420
http://dx.doi.org/10.1186/s40164-021-00211-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7923338/
https://www.ncbi.nlm.nih.gov/pubmed/33653420
http://dx.doi.org/10.1186/s40164-021-00211-8

Ejemplares similares